ALLOGENE THERAPEUTICS INC. - COMMON STOCK

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

12 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

05 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

28 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia

16 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

16 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

04 Jan 2024 15:15:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

04 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology

09 Dec 2023 11:00:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in December Investor Conference

01 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting

03 Nov 2023 11:00:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting

03 Nov 2023 11:00:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update

02 Nov 2023 15:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology

02 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in November Investor Conferences

30 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023

26 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer

16 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

27 Sep 2023 08:09:21 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in September Investor Conference

05 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Earl Douglas as General Counsel

14 Aug 2023 07:30:38 By Nasdaq GlobeNewswire